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connection with the artery lumen of  some inti- 
mal capillaries may render these vessels mechani- 
cally weak and more likely to bleed. Intramural 
hemorrhage may promote further angiogenesis. 
Angiogenesis n the plaque may indirectly promote 
plaque rupture through the activation of endothelial 
cell proteases and matrix metalloproteases. 4 Infimal 
vessels may regulate inflammatory cell recruitment 
in lesions. The areas of macrophage infiltration in 
the fibrous cap over the lipid core of vulnerable 
lesions correspond to regions at risk for rupture. 
3. Restenosis after angioplasty or stent placement. 
Intimal neovascularization is more prevalent in 
restenotic lesions3 Increased adventitial anglo- 
genesis is observed in arterial balloon-injury mod- 
els, but the effects of angiogenesis inhibitors a e
not fully known.5 Treatments with endothelial cell 
inhibitors after injury may impede the repair of the 
arterial endothelium, which may attenuate the 
denudation-injury. 6 Treatments with endothelial 
cell growth factors may augment injury. 7 
4. Regression, In animal models of diet-induced 
atherosclerosis, cholesterol reduction is associat- 
ed with regression of plaque neovascularization 
and a minimal regression of plaque size. s 
5. Transplant-associated atherosclerosis. 9 
6. Vasctflitis. 1° 
Sttmmary 
Therapeutic applications of angiogenesis inhibitors 
and stimulators for atherosclerosis may be stage- 
appropriate and not paradoxic. 
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RESULTS TO DATE: CLINICAL STUDIES--- 
THERAPEUTIC ANGIOGENESIS IN THE 
PERIPHERAL AND CORONARY BEDS 
Stephen Epstein, MD 
Washington Hospital Center 
Washington, DC 
As many as 50% of  patients with atherosclerosis 
lack currently identified risk factors (such as hyper- 
tension, smoking, hypercholesterolemia, and dia- 
betes), an observation i dicating that additional fac- 
tors predisposing to atherosclerosis are as yet unde- 
tected. Injury to the vessel wall and the associated 
inflammatory response to injury are now generally 
recognized as the essential components of atheroge- 
nesis. However, the triggers that initiate and sustain 
the inflammatory process have not been definitively 
identified. One candidate trigger of  both inflamma- 
tory and autoimmune responses--the subject of  this 
talk--is infection. 
Infect ion as a contr ibutor  to atherosclerosis 
Evidence began accumulating over 25 years ago 
suggesting that herpes viruses may possibly play a role 
in the development of atherosclerosis. It  was found 
that Marek's disease virus, an avian herpes virus, 
caused typical atherosclerotic lesions in chickens, and 
when smooth muscle ceils (SMCs) were infected with 
the virus in vitro, cholesterol accumulated. 
Presence o f  pathogens in the vessel wall and sero- 
epidemiologic studies 
Evidence in humans suggesting infection predis- 
poses to atherosclerosis derived from studies demon- 
strating that infectious agents reside in the wall of 
JOURNAL OF VASCULAR SURGERY 
Volume 31, Number 6 Lifeline Research Meeting Abstracts 1261 
atherosclerotic vessels (initially, cytomegalovirus 
[CMV] and later Chlamydia pneumoniae), and sero- 
epidemiologic studies demonstrating an association 
between the pathogen-specific IgG antibodies and 
atherosclerosis. The first such seroepidemiologic asso- 
ciations published related to CMV, which were later 
followed by the publication of similar associations 
between atherosclerosis and herpes implex (HSV) 
type I and type 2, Cpneumoniae, Helicobactorpylori, 
and, most recently, hepatitis A virus. Moreover, 
prospective studies of the relation between CMV 
seropositivity and the subsequent development of
restenosis following coronary angioplasty revealed an 
increased incidence of restenosis n patients eroposi- 
five for CMV. 
Direct effects of  infectious agents on cellular 
components of the vessel wall that could predis- 
pose to atherosclerosis 
Additional evidence favoring causality has 
derived from investigations demonstrating that 
infection of cells residing in the vessel wall cause cel- 
lular and molecular changes conducive to atheroge- 
nesis. These studies have demonstrated the follow- 
ing proatherosclerotic effects of infection: 
1. SMC accumulation 
A. Inhibition of the tumor suppressor gene, p53 
B. Stimulation of the secretion of growth fac- 
tors or increasing expression of growth 
factor eceptors 
C. Inhibition ofapoptosis 
D. Augmentation ofSMC migration 
II. Lipid accumulation 
A. Increased accumulation fcholesterol 
B. Decrease in lysosomal and cytoplasmic cho- 
lesterol ester hydrolytic activity 
C. Enhanced scavenger receptor activity 
III. Endothelial dysfunction 
IV. Procoagulant effects 
A. Increased endothelial cell synthesis of tissue 
factor 
B. Increased thrombin gcneration 
C. Increased platclet adherence 
D. Decreased prostacyclin and thrombomod- 
ulin generation 
V. Increased expression of cytokines, chemoldnes, 
and cellular adhesion molecules 
Delivery of pathogen to the vessel wall 
Both CMV and Cpnuemoniae re present in ath- 
erosclerotic arteries, and CMV DNA has been found 
in restenosis lesions. It is possible that these and 
other pathogens directly infect the vessel wall and 
either persist in a latent state, produce an abortive 
infection, or replicate at a low (and possibly inter- 
mittent) level. An alternative possibility focuses on 
the circulating monocyte as a "Trojan horse'--a 
vehicle for delivery of pathogen to the vessel wall. 
That this can occur is indicated by the fact that these 
cells harbor latent CMV and that C pneumoniae is 
capable of replicating in a macrophage c ll line. 
With CMV, it is believed that the virus infects 
monocyte precursors present in bone marrow, and 
that the viral genome persists in these ceils. Given 
that CMV infection develops in bone marrow trans- 
plant recipients eronegative for CMV but whose 
donors are CMV seropositive, it is likely that 
myelomonocytic precursor ceils act as a reservoir of 
CMV, and that circulating monocytcs then act as a 
vector, delivering the virus to sites of vascular 
inflammation or injury. For Chlamydia species, it is 
believed that pulmonary alveolar macrophages act as 
the vector, picldng up the pathogen during the 
course of a pulmonary infection. 
Systemic alterations produced by infectious 
agents that could predispose to atherosclerosis 
without the need for pathogen residence in the 
vessel wall 
Given the evidence outlined above, it would be 
reasonable to conclude that one set of mechanisms 
by which infection contributes to atherosclerosis 
consists of direct effects of the pathogen on the ves- 
sel wall, mediated by mechanisms requiring the actu- 
al presence of the pathogen locally. However, other 
mechanisms not requiring local residence are also 
most likely to be operative. For example, infection 
causes a spectrum of systemic effects, producing 
fever, malaise, myalgias anda panoply of signs and 
symptoms, including alterations in the circulating 
levels of such factors as cytokines, acute phase reac- 
tants, white blood cells, and responses mediated by 
the immune system, such as an increase in antibod- 
ies targeted to the invading pathogen. These sys- 
temic manifestations f infection can be either pro- 
found or subtle; importantly, however, these 
changes provide additional mechanisms, other than 
local residence-requiring direct vascular effects, 
whereby pathogens could influence the course of 
atherosclerosis. 
That infection might exert effects on an injured 
vessel wall that do not necessitate pathogen resi- 
dence in the vessel is uggested by the results of 
studies to determine whether CMV infection 
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increases the neointimal response to vascular injury 
in the rat. Although rats infected with CMV mani- 
fested an increased neointimal response to injury, 
virus was essentially absent from the injured segment 
of the vessel; neither eplicating virus nor viral pro- 
teins could be detected, despite the fact that repli- 
cating virus could be isolated from such tissues as 
the spleen and salivary gland. 
Circulating pathogen-derived or pathogen-stim- 
ulated factors that could induce changes in the 
vascular wall 
Studies have shown that various circulating 
pathogen-derived or pathogen-stimulated factors 
can elicit changes in monocyte/macrophages that
could be proatherogenic, and that might even con- 
tribute to plaque instability. For example, bacterial- 
ly-derived lipopolysaccharide (LPS) and chlamydial 
or human hsp induce tissue necrosis factor-~ (TNF- 
~) secretion by macrophages, a cytokine that stim- 
ulates endothelial cells to express adhesion mole- 
cules. These factors also stimulate ndothelial and 
smooth muscle cells to express interleukin-1 (IL-1), 
mRNA and IL-6, and preferentially stimulate 
endothelial cells to express E-selectin and ICAM- 
1. In addition, several surface antigens of 
Porphyromonasgingivalis,  gram negative bacterium 
causally related to periodontitis, timulate BALB/c 
peritoneal macrophages to secrete IL-1 beta. TNF- 
a, IL-1, IL-6, and ICAM-1 have all been related to 
atherogencsis. 
The above responses can be considered as possi- 
bly contributing to the development of atheroscle- 
rosis. In addition, LPS, chlamydial hsp, and human 
hsp have also been shown to stimulate the secretion 
of matrix metalloproteinases (MMPs). These 
enzymes have the capacity to degrade connective tis- 
sue and thereby are believed to predispose, by weak- 
ening the fibrous cap of atheromatous lesions, to 
plaque rupture. Thus, pathogens may not only stim- 
ulate responses that are proatherogenic, but they 
may also contribute to the precipitation of plaque 
instability and rupture, the most common cause of 
death from CAD. 
Individual variations in host-pathogen interac- 
tions that influence inflammatory activity and 
the susceptibility to pathogen-induced contribu- 
tion to vascular disease 
Inf lammatory activity. Although many epi- 
demiologic studies have demonstrated that seropos- 
itivity to several infectious agents is associated with 
increased CAD risk, the data are inconsistent with 
other studies howing no increased risk. One possi- 
ble explanation for this disparity is that whether 
prior infection, as reflected by seroP0sitivity , con- 
tributes to CAD risk may depend, at least in part, 
on the capacity of the host to suppress pathogen 
inflammatory activity. The validity of this concept is 
suggested by a study demonstrating that (1) while 
some individuals seropositive to CMV have elevated 
CRP levels, in others, CRP is within the normal 
range, and (2) the highest CAD prevalence occurs 
in the subgroup with combined CMV seropositivi- 
ty and elevated CRP levels. When adjusted for CAD 
risk factors, the odds ratios for CAD were 1.3 in the 
subgroup with CMV seropositivity alone (P = .7), 
2.3 in the subgroup with elevated CRP levels alone 
(P = .2), and 4.3 in the subgroup with combined 
CMV seropositivity and elevated CRP levels (P = 
.01). 
Humoral and cellular immune responses. A 
second possible explanation for the disparity in sero- 
epidemiologic studies may relate to the type of 
immune response mounted by the host to CMV 
infection. Thus, CMV appears to be a significant 
predictor of CAD for women. Importantly, howev- 
er, the data showed that the type of immune 
response to CMV determines whether CMV predis- 
poses to CAD. In women evaluated for CAD by 
coronary angiography, blood samples were tested for 
humoral (Ab+) and cellular (Tc+) responses to 
CMV. Susceptibility o CMV-related CAD was lim- 
ited to those women with a humoral immune 
response to CMV (Ab+/Tc- or Ab+/Tc+). The 
prevalence of CAD in those without an antibody 
response but with a cellular esponse (Ab-/Tc+) was 
similar to that of the women without apparent prior 
CMV infection (Ab-/Tc-). 
Pathogen burden as a determinant of  elevated 
CRP and CAD risk 
If infection plays a role in atherogenesis, it would 
be highly likely that multiple pathogens would be 
causally involved and, importantly, that CAD risk 
would relate to the aggregate pathogen load (what 
we have termed pathogen burden). Preliminary stud- 
ies have suggested that this concept may be vail& 
C pne~tmoniae has been shown to increase 
atherosclerosis in both a rabbit model and a mouse 
apoE knockout model of atherosclerosis. Similar 
results have been demonstrated for CMV infection 
in the apoE knockout model. In addition, as noted 
above, in an acute injury model (balloon injury of a 
rat carotid artery), infection with CMV increases the 
resulting neointimal response. 
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Summary  and conclus ions 
In summary, there is an increasing body of  infor- 
mation compatible with the concept hat infectious 
agents contribute to the development o f  atherosde- 
rosis and to plaque instability and rupture. These 
possibilities are strengthened by the multiple investi- 
gations providing cellular and molecular mechanistic 
support for such roles and by investigations demon- 
strating that certain pathogens can exacerbate l sion 
development in animal models. It  is equally clear, 
however, that no simple relationship exists between 
infection and atherogenesis. As with other infectious 
diseases, the propensity for a given infectious agent 
to contribute to the development o f  atherosclerosis 
will depend on host-pathogen i teractions. This in 
turn will determine susceptibility to pathogen inflam- 
matory activity and therefore to atherogenic poten- 
tial. And if additional studies support an important 
antoimmtme component  o atherogenesis, the type 
of  hurnoral and cellular immune responses mounted 
by the host to infection may determine whether a 
particular pathogen will contribute to atherosclerotic 
lesion development in a particular host. 
As the case for a role o f  infection grows, the exist- 
ing paradigms to explain the natural history o f  the 
clinical manifestations o f  CAD can be expanded. For 
example, it had been appreciated many years ago that 
atherosclerosis does not progress as a slow gradual 
process, but rather that the underlying progressive 
nature o f  the disease is punctuated by intermittent 
acute exacerbations. This has been appreciated both 
in the clinic and by morphologic investigations ofath- 
erosclerotic plaques. The concept hat infection plays 
a role in atherosclerosis fits this model  very well. 
Thus, with the product ion of  persistent subclinical 
infections causing a chronic inflammatory state (lead- 
ing to activation of  inflammatory cells and of  immune 
processes), infectious agents could contribute to grad- 
ual plaque enlargement. However, punctuation of  this 
low-grade persistent activity by recurrent acute infec- 
tions or intermittent reactivation of  latent infections, 
whether clinically overt or silent, could cause acute 
exacerbations o f the atherosclerotic process, including 
plaque rupture and thrombotic occlusion. 
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RESTENOSIS: HOW AND WHY SMOOTH MUS- 
CLE CELLS PROLIFERATE 
Michael A. Reidy, l'hD 
University of Washington 
Seattle, Wash 
A goal o f  many vascular biologists has been to 
understand why smooth muscle ceils (SMCs) prolifer- 
ate. Early work focused on identification o f  mito- 
gen(s) that were thought necessary for SMC replica- 
tion, and while a great deal of  effort was expended, 
the conclusions from these studies have not benefited 
our understanding of  how lesions develop in man. In 
part this may reflect differences in animal models and 
in experimental conditions, but it also relates to an 
assumption that the response of  any SMC will be sim- 
ilar. I f  true then results obtained from experimenta- 
tion with a healthy artery o f a small mammal would 
be directly applicable to understanding cell replication 
in other arteries including those of  man. We have 
found this assumption to be incorrect but not neces- 
